Seroquel Weight Gain Problems Kept From Doctors
Internal documents disclosed during the litigation over Seroquel suggest that AstraZeneca continued to promote the antipsychotic drug as weight neutral, years after clinical evidence demonstrated significant Seroquel weight gain problems for users, which could lead to diabetes and other serious side effects.
A 2001 letter from a marketing official revealed that the pharmaceutical giant had a global strategy aimed at casting Seroquel as “weight neutral”, according to a report by Bloomberg News. This letter was written four years after the drug company’s own research found “clinically significant” weight gain among users of Seroquel.
The evidence was presented during a pretrial examination of John Patterson, a former AstraZeneca executive who reported directly to the company’s CEO. The 2001 letter appeared to directly contradict a 1997 email from one of AstraZeneca’s doctors that reported 45% of patients gained significant weight with Seroquel in a year.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
Seroquel (quetiapine fumarate) is an atypical-antipsychotic that is a top selling drug for AstraZeneca, generating nearly $4.45 billion in sales in 2008. Approved by the FDA in 1997 for the treatment of schizophrenia, it is also commonly used off-label for treatment of anxiety, obsessive dementia, compulsive disorders and autism. Seroquel has been used by more than 19 million people worldwide.
Thousands of people have filed a Seroquel lawsuit against AstraZeneca alleging that the drug maker failed to adequately warn about the increased risk of diabetes, which is caused by the drug’s weight gain side effects. Among other things, plaintiffs argue that AstraZeneca actively concealed the diabetes risk with Seroquel when asked by U.S. doctors, even though they knew or should have known that there was a connection.
All federal Seroquel cases are consolidated for pretrial litigation in an MDL, or multidistrict litigation, that is centralized in the U.S. District Court for the Middle District of Florida.
Other documents produced during Patterson’s testimony were used to used to suggest the company was promoting Seroquel for uses that had not been determined to be safe and effective by the FDA. A “Seroquel Strategy Summary” in 2000 reportedly described off label promotion as a goal.
While doctors are free to prescribe drugs for non-approved uses, it is illegal under current federal regulations for a drug company to promote their medications for such “off-label” use. Patterson estimated during his testimony that off-label use accounted for 30% to 40% of Seroquel sales, and admitted that percentage could be higher.
or off-label uses.
DianeJuly 24, 2014 at 7:00 pm
I have concerns about Seroquel in which I was prescribed for years please contact me about this Thank You,
BrandyFebruary 4, 2010 at 6:10 am
The weight gain was something I was completely unaware of. I gained two sizes, before I realized what it was making me gain weight. I am off of the drug now.
BarbaraNovember 22, 2009 at 9:56 am
At the time, my son was 7 years old. Here in Alaska, subsequently, Robert has been diagnosed bi-polar disorder and was subscribed Seroquel for over a year. He put on the weight, but, the bad thing about this, the doctor he was seeing at the time, was passed out most of the time. Only 7 years old, was taking 4 times a day?!
"*" indicates required fields
More Top Stories
A new report indicates the U.S. Navy is struggling to process tens of thousands of Camp Lejeune water poisoning claims due to a lack of resources.
A group of plaintiffs have filed a motion with the U.S. JPML seeking consolidation of all Bard implanted port lawsuits before one judge for pretrial proceedings.
A Tepezza hearing loss lawsuit accuses the manufacturer of failing to provide adequate warning about the risks of the thyroid eye disease drug.